Ascendis Pharma A/S (NASDAQ:ASND) Earns “Overweight” Rating from Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research note issued on Friday,Benzinga reports. They currently have a $170.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 34.38% from the company’s previous close.

Several other brokerages have also recently weighed in on ASND. Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. JPMorgan Chase & Co. dropped their target price on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. TD Cowen lifted their target price on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Wells Fargo & Company lifted their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Finally, Jefferies Financial Group lifted their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $191.77.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $126.51 on Friday. Ascendis Pharma A/S has a fifty-two week low of $90.13 and a fifty-two week high of $161.00. The stock has a market cap of $7.67 billion, a price-to-earnings ratio of -13.59 and a beta of 0.66. The firm’s 50-day simple moving average is $132.30 and its 200 day simple moving average is $132.66.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, sell-side analysts predict that Ascendis Pharma A/S will post -7.35 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ASND. Groupama Asset Managment purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at $60,000. Price T Rowe Associates Inc. MD grew its position in shares of Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after purchasing an additional 267,881 shares in the last quarter. Acadian Asset Management LLC grew its position in Ascendis Pharma A/S by 1,461.1% in the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after acquiring an additional 234,446 shares in the last quarter. Finally, Avoro Capital Advisors LLC grew its position in Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after acquiring an additional 229,995 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.